Ing Group N.V. (IND) 0.00 0.00

IND DAIRYTECH
(IND) 0.00 0.00

Last Trade:	0.48	Day Range:	0.48 - 0.48
Trade Time:	Aug 03	52wk Range:	0.225 - 0.50
Prev. Close:	0.48	Market Cap:	0
Open:	0.00	Div Yield:
Volume:	0	PE:
EPS:	0.00

The Latest On IND

Investor Ideas' Biopharmaceutical Stock to Watch: Idenix Pharmaceuticals Soars on HCV Development News 1/9/12 12:10pm

Idenix Reports Advancement of HCV Development Pipeline 1/9/12 7:01am

Oncothyreon Files Investigational New Drug Application for ONT-10 12/20/11 8:01am

Aeterna Zentaris: FDA Grants IND to Investigator at Baylor College of Medicine for Phase 2A Trial with AEZS-130 in Cancer Cachexia 11/28/11 7:31am

ImmunoGen, Inc. Announces Submission of IND for Wholly Owned Product Candidate for Non-Hodgkin's Lymphoma 9/22/11 3:02pm

Morning Market Movers 8/16/11 8:47am

FDA Approves Trial of Adamis Pharmaceuticals Product Candidate to Treat Prostate Cancer 6/8/11 8:32am

CEOWORLD Top 15 Stocks Picks Below $10- RMTR, APP, ACAD, HRZ, AIB, HNSN, QPSA, JRJC, TASR, RPRX, ONTY, LOOK, CT, SHZ, ESLR 4/26/11 7:30am

Adamis Pharmaceuticals Files IND for Product Candidate to Treat Prostate Cancer 3/9/11 9:43am

Dendreon Rises on Provenge Update - Analyst Blog 1/10/11 10:01am

Dendreon Rises on Provenge Update - Analyst Blog 1/10/11 9:45am

Trading Alert: OTCBB Stocks to Watch; (OTCBB: AMOK), (OTCBB: ESPH), (OTCBB: ACTC), (OTCBB: GNBT) 1/7/11 2:21pm

Investor Ideas' Biopharmaceutical Stock to Watch: Idenix Pharmaceuticals Soars on HCV Development News 1/9/12

Idenix Reports Advancement of HCV Development Pipeline 1/9/12

Oncothyreon Files Investigational New Drug Application for ONT-10 12/20/11

Aeterna Zentaris: FDA Grants IND to Investigator at Baylor College of Medicine for Phase 2A Trial with AEZS-130 in Cancer Cachexia 11/28/11

ImmunoGen, Inc. Announces Submission of IND for Wholly Owned Product Candidate for Non-Hodgkin's Lymphoma 9/22/11

Morning Market Movers 8/16/11

FDA Approves Trial of Adamis Pharmaceuticals Product Candidate to Treat Prostate Cancer 6/8/11

CEOWORLD Top 15 Stocks Picks Below $10- RMTR, APP, ACAD, HRZ, AIB, HNSN, QPSA, JRJC, TASR, RPRX, ONTY, LOOK, CT, SHZ, ESLR 4/26/11

Adamis Pharmaceuticals Files IND for Product Candidate to Treat Prostate Cancer 3/9/11

Dendreon Rises on Provenge Update - Analyst Blog 1/10/11

Trading Alert: OTCBB Stocks to Watch; (OTCBB: AMOK), (OTCBB: ESPH), (OTCBB: ACTC), (OTCBB: GNBT) 1/7/11

Trade IND
NOW!

Partner Headlines

Press Releases

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 2/9/12 Business Wire Story

Neurocrine Biosciences Reports Fourth Quarter and Year End 2011 Results 2/8/12 Newswire Story

Sangamo BioSciences Reports Fourth Quarter and Full Year 2011 Financial Results 2/8/12 Newswire Story

ZIOPHARM Announces FDA Acceptance of IND for Oral Palifosfamide 2/6/12 GlobeNewswire Story

OptiNose Files Investigational New Drug Application to use Sumatriptan Delivered with its Novel Drug Delivery Technology 2/2/12 Business Wire Story

Shire and Sangamo Collaborate to Develop Therapeutics for the Treatment of Hemophilia and Other Monogenic Diseases 2/1/12 Newswire Story

Athersys Awarded $3.6 Million in Grant Funding for Stem Cell Product Development 2/1/12 GlobeNewswire Story

NanoViricides Inc. Submits Pre-IND Briefing Document for its Anti-Influenza drug, FluCide™, to the US FDA 1/31/12 Business Wire Story

Cannibus Science (CBIS), Fuse Science (DROP) Why Xtremepicks is loading up on these monster winners 1/30/12 Emailwire Story

Cancer Patient Success Prompts Cannabis Science To Begin FDA Investigational New Drug (IND) Application Process 1/25/12 Business Wire Story

Avila Announces FDA Allowance of Partner Clovis Oncology's IND Application for CO-1686, an Oral EGFR Mutant-Selective Inhibitor 1/19/12 Business Wire Story

Get the latest IND stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for IND DAIRYTECH stock price.

IND DAIRYTECH by YCharts

Ing Group N.V. (IND) 0.00 0.00

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On IND

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social